The FDA announces policy for digital pathology devices for remote use during COVID-19

The Food and Drug Administration (FDA) issued a guidance to help expand the availability of devices for remote reviewing and reporting of scanned digital images of pathology slides during the COVID-19 pandemic. Increased availability of these devices may help to facilitate continuity of patient care by preventing disruptions to critical pathology services rendered by clinical laboratories, hospitals, and other healthcare facilities, and by reducing healthcare personnel contact and risk of exposure to SARS-CoV-2.

For more information on this guidance click HERE